Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00181688
Status:
COMPLETED
Last Update Posted:
2012-12-05
First Post:
2005-09-12
Brief Title:
Iressa ZD1839 Plus Anastrozole Arimidex in Patients With Ovarian Cancer
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
A Phase II Study of ZD1839 Iressa Plus Anastrozole Arimidex in Patients With Relapsed Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to determine the effects good and bad Iressa plus anastrozole has on patients with relapsed ovarian cancer
Detailed Description:
Patients will receive Iressa and anastrozole orally once daily until treatment is ended Treatment will end if any of the following occur Unacceptable adverse effects bowel obstruction initiation of systemic chemotherapy development of new ascites or pleural effusions development of co-morbid disease or disease progression
Patients will be given a drug log in which to record the date and time they take their pills as well as any symptoms and concomitant medications
Patients will be seen monthly for the following tests and procedures a physical examination and repeat blood work Patients who remain free of clinical symptoms should have repeat abdominalpelvic CT scans and chest x-rays on an every 3 month basis
Patients will be given a drug log in which to record the date and time they take their pills as well as any symptoms and concomitant medications
Patients will be seen monthly for the following tests and procedures a physical examination and repeat blood work Patients who remain free of clinical symptoms should have repeat abdominalpelvic CT scans and chest x-rays on an every 3 month basis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None